H.C. Wainwright analyst Matthew Caufield downgraded Iveric bio (ISEE) to Neutral from Buy with a price target of $40, up from $35, after the company entered into a definitive agreement to be acquired by Astellas Pharma (ALPMY) for $40 per share, which represents an equity value of $5.9B.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Iveric bio downgraded to Neutral from Outperform at Credit Suisse
- Guggenheim downgrades Iveric bio after deal, doesn’t expect other bidders
- Iveric bio downgraded to Equal Weight from Overweight at Morgan Stanley
- Optics of Iveric deal may pressure Apellis near-term, says Baird
- Iveric bio downgraded to Neutral from Outperform at Wedbush